Resuscitace při traumatu s nízkým titrem skupiny O plná krev nebo produkty (TROOP)
The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
Trauma is one of the leading causes of death in the United States, and disproportionately affects the young, killing those who might otherwise have lived long and productive lives. Injuries account for more years of potential life lost before age 75 than any other cause. Hemorrhage remains the most common cause of preventable death after injury, and blood transfusion is an essential part of treatment. Modern blood banking practices separate donated whole blood into components. The current standard of care in trauma transfusion is the balanced administration of equal numbers of units of blood components (packed red blood cells, plasma, and platelets), effectively attempting to reconstitute whole blood. A renewed approach to blood transfusion therapy in trauma is to use whole blood from the outset, which has not been separated. Compared with component therapy, whole blood offers several potential advantages, but there are only a small number of, mostly observational, studies comparing whole blood and component therapy, and they are very heterogeneous.
The TROOP trial will include injured adults with hemorrhagic shock anticipated to require massive blood transfusions, who will be randomized to receive either whole blood (LTOWB) or blood components. This will allow a direct comparison to see if one type of transfusion is more strongly associated with improved clinical outcomes over the other.
The knowledge gained from this clinical trial will transform the way in which massively bleeding trauma patients are transfused. The trial is exceedingly well positioned to improve mortality from trauma and reduce the number of preventable deaths resulting from hemorrhagic shock.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35294
- University of Alabama at Birmingham, UAB Hospital
-
-
California
-
Los Angeles, California, Spojené státy, 90033
- Los Angeles County + University of Southern California (LAC + USC) Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Spojené státy, 70112
- University Medical Center New Orleans LCMC Health
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21201
- University of Maryland Medical Center
-
-
Missouri
-
St Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
-
North Carolina
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Atrium Health Wake Forest Baptist
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45267
- University of Cincinnati Medical Center
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97239
- Oregon Health and Sciences University Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Penn Presbyterian Medical Center
-
-
Texas
-
Houston, Texas, Spojené státy, 77030
- University of Texas Health Science Center Houston
-
San Antonio, Texas, Spojené státy, 78229
- University of Texas Health San Antonio and University Health System
-
-
Washington
-
Seattle, Washington, Spojené státy, 98104
- Harborview Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53226
- Froedtert Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Adult trauma patient (estimated age > 15 or weight > 50 kg, if age unknown)
-
Patient taken to trauma center directly from scene
-
Commencement of blood transfusion (PRBC, plasma or LTOWB), in pre-hospital or in-hospital setting
-
Activation of site-specific Massive Hemorrhage Protocol or Massive Transfusion Protocol
-
Traumatic injury with at least one of the following:
- Confirmed or suspected acute major bleeding
- Assessment of Blood Consumption (ABC) Score ≥2
Exclusion Criteria:
- Patients who have received, prehospital or in-hospital more than two units of LTOWB; the equivalent in components (two units of packed red blood cells and two units of plasma); or a combination of the two (more than one unit of LTOWB, one unit of packed cells, and one unit of plasma). Most trauma centers hold two units of either packed red blood cells (with two units of plasma) or two units of LTOWB in the emergency department. This stock is used to initiate transfusion, while the massive hemorrhage protocol is activated from the blood bank.
- Patients transferred from another hospital
- Children <15 years (in most communities, patients aged 15-18 years are treated at adult trauma centers, and patients in this age group frequently suffer life-threatening injuries, and will therefore be included)
- Known prisoners, defined as individuals involuntarily confined or detained in a penal institution (including juvenile detention, involuntary psychiatric commitment, or court-ordered residential substance abuse treatment)
- Moribund patients expected to die within 1 hour
- Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)
- Patients with known "do not resuscitate" orders prior to randomization
- Patients who refuse the administration of blood products
- Individuals with a research "opt out" bracelet.
- Greater than 20% total body surface area (TBSA) burns
- Suspected inhalation injury victims
- Patients who are obviously pregnant on clinical examination or known to be pregnant as provided by the subject or legally authorized representative
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Aktivní komparátor: LTOWB
Participants randomized to receive (Low Titer O Whole Blood [LTOWB]) |
Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously. |
|
Aktivní komparátor: Components
Participants randomized to receive the component blood products. |
Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
6-hour Mortality
Časové okno: First 6 hours after randomization
|
Participant vital status at 6-hours following randomization (randomization defined as product container is opened for administration to participant) |
First 6 hours after randomization
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
24-hour Mortality
Časové okno: First 24 hours after randomization
|
Participant vital status at 24-hours following randomization |
First 24 hours after randomization
|
|
Hospital/30-day Mortality
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Participant vital status at hospital discharge or 30-days post randomization (whichever the earlier) |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Incidence of Pre-specified Complications
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
The number of participants experiencing pre-specified complications. Pre-specified complications include: Acute kidney injury; Ventilator-associated pneumonia; Multiorgan failure; Transfusion-related hyperkalemia; Transfusion-related hypocalcemia; Transfusion associated circulatory overload; Acute respiratory distress syndrome; Symptomatic and asymptomatic deep vein thrombosis; Symptomatic and asymptomatic pulmonary embolism; Bleeding after hemostasis requiring intervention; Stroke; Myocardial infarction; Abdominal compartment syndrome; Transfusion-related allergic reactions; Febrile non-hemolytic transfusion reaction; Systemic inflammatory response syndrome; Sepsis; Alloimmunization in women of childbearing age |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Adjudicated Primary Cause of Death
Časové okno: 30-days post randomization
|
Primary cause of death as reviewed and determined by the study investigators (consensus) |
30-days post randomization
|
|
Length of Stay (Hospital and Intensive Care Unit)
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Number of hours hospitalized (includes both hospital and intensive care unit time) |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Hospital-, Ventilator- and Intensive Care Unit-free days
Časové okno: 30-days post randomization
|
Number of days participant was alive and out of the hospital; number of days participant was not on a ventilator; and the number of days the participant was not in the intensive care unit. |
30-days post randomization
|
|
Incidence of major surgical procedures
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
The proportion of participants undergoing major surgical procedures. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Time to hemostasis in those undergoing procedures with a hemostatic component
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete) following emergency department arrival. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Number and type of blood products used until hemostasis is achieved and from hemostasis to 24 hours after randomization
Časové okno: First 24 hours after randomization
|
The number of units and type of blood products (e.g. whole blood, packed red blood cells, platelets, plasma, etc.) |
First 24 hours after randomization
|
|
Discharge destination
Časové okno: At hospital discharge or 30-days post randomization (whichever the earlier)
|
Discharge destination will be measured as a categorical variable. Categories will be tallied and compared between the two study arms. Example variables include: discharged to home, discharged to another primary care facility, discharged to hospice, etc. |
At hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Functional status
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Functional status will be measured by Extended Glasgow Outcome Scale (GOSE). The GOSE is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Patient's quality of life
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Quality of life will be measured by the Euroqol Group's EQ-5D quality of life measurement. The EQ-5D is a patient-reported questionnaire assessing health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). Lower EQ-5D scores are associated with better outcome. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Jan Jansen, MBBS, PhD, University of Alabama at Birmingham
Publikace a užitečné odkazy
Obecné publikace
- Meizoso JP, Cotton BA, Lawless RA, Kodadek LM, Lynde JM, Russell N, Gaspich J, Maung A, Anderson C, Reynolds JM, Haines KL, Kasotakis G, Freeman JJ. Whole blood resuscitation for injured patients requiring transfusion: A systematic review, meta-analysis, and practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2024 Sep 1;97(3):460-470. doi: 10.1097/TA.0000000000004327. Epub 2024 Mar 27.
- Jansen JO, Pedroza C, Novelo LL, Hao T, DeWildt GR, Coton CF, Mansoor K, Stephens SW, Marques MB, Stubbs JR, Richter JR, Wang HE, Holcomb JB, DeSantis SM. Trauma resuscitation with Low-Titer Group O Whole Blood Or Products: study protocol for a randomized clinical trial (the TROOP trial). Trials. 2025 Aug 2;26(1):266. doi: 10.1186/s13063-025-08971-y.
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Aktuální)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- IRB-300010517
- 1UG3HL157401-01A1 (Grant/smlouva NIH USA)
- 1U24HL157310-01A1 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .